#USA #Washington #NABR #CITES #Macaca

NABR Applauds CITES Decision

The National Association for Biomedical Research (NABR) recently expressed its satisfaction with the conclusion reached by the CITES Standing Committee regarding the trade in long-tailed macaques from Cambodia. On February 5, 2025, the decision was made not to implement a suspension on the trade of these primates, an outcome that underscores the importance of a scientifically rigorous approach to wildlife trade regulations.

This decision is particularly notable as it reflects a collective support from multiple nations, including Japan, Canada, and the United States, all of whom urged caution before adopting any potential trade suspensions. The NABR's president, Matthew R. Bailey, emphasized that such decisions must be based on thorough consideration of facts. This sentiment is crucial in the fight against misinformation propagated by extreme activist organizations, which often prioritize pseudoscience over evidence-based policy.

During the recent CITES meeting in Geneva, no nation supported the Secretariat's recommendation to halt trade due to misconstrued claims about the export of macaques from Cambodia. Instead, participating countries advocated for a careful review of the new information submitted by Cambodia. This approach is meant to ensure that any policies enacted are grounded in verifiable evidence rather than conjecture.

This prudent decision by the CITES Standing Committee allows the Secretariat to conduct a comprehensive assessment and send a formal delegation to Cambodia. Such steps are essential to maintaining transparency and ensuring that all actions taken are well-informed.

From the NABR's perspective, this outcome is a significant victory not only for scientific integrity but also for public health. The association highlights that biomedical research often relies on the availability of long-tailed macaques for vital studies aimed at developing treatments for infectious diseases, cancer, and other serious health issues.

Bailey remarked, “The decision underscores the essential nature of thoughtful consideration in making decisions that have far-reaching implications. The international community’s rejection of unfounded trade suspensions is a resounding affirmation of our commitment to scientific integrity.”

Looking ahead, NABR remains resolute in its mission to advocate for policies rooted in science and fact. The association focuses on ensuring that decisions related to international trade in wildlife align with ethical biomedical research and support medical advancements.

The NABR is committed to collaborating with global stakeholders to promote transparency and uphold responsible use of research animals in the pivotal advancements in health sciences. Bailey concluded his statement by reaffirming the organization's dedication to these principles, underscoring the necessity for continuous dialogue and support among the scientific community, policymakers, and public interest advocates.

About NABR

Founded in 1979, the National Association for Biomedical Research is the sole nonprofit organization dedicated to advocating for the humane use of animals in biomedical research, education, and testing. The association comprises over 340 members, including universities, medical and veterinary schools, teaching hospitals, pharmaceutical and biotechnology companies, and patient groups. NABR's work is pivotal in promoting humane and responsible animal research to enhance global health for both humans and animals. For more information about NABR and its mission, visit www.nabr.org or contact Eva Maciejewski at (202) 967-8305.